Science Opportunity Leadership Contact Request Deck
Spectracore Therapeutics — Antimicrobial Photodynamic Therapy

Redefining Infection Control.

Harnessing the precision of red-light photodynamics to eliminate drug-resistant pathogens at the source — without antibiotics, without resistance, without compromise.

Request Investor Deck Explore the Science
$14B
Addressable Market
0%
Resistance Reported
3rd
Generation aPDT
Antimicrobial Photodynamic Therapy Red Light Pathogen Elimination Zero Antibiotic Resistance FDA Regulatory Pathway Clinical Stage Development Physician-Led Innovation Antimicrobial Photodynamic Therapy Red Light Pathogen Elimination Zero Antibiotic Resistance FDA Regulatory Pathway Clinical Stage Development Physician-Led Innovation
The Science

Light as a
Therapeutic Weapon

Antimicrobial Photodynamic Therapy (aPDT) uses targeted red-light wavelengths to activate photosensitizing agents that generate reactive oxygen species — destroying pathogens at the cellular level without damaging surrounding tissue.

Unlike conventional antibiotics, aPDT operates through a multi-target mechanism that pathogens cannot adapt to. No resistance has been reported in over two decades of clinical research — a singular advantage in the age of AMR.

Spectracore's proprietary platform advances third-generation aPDT formulations with enhanced tissue penetration, targeted delivery, and optimized photosensitizer chemistry — purpose-built for the clinical settings where resistance poses the greatest threat.

Platform Advantages

Why aPDT Wins

01
Zero Resistance Mechanism
aPDT kills through simultaneous multi-target oxidative stress — a mechanism pathogens cannot evolve resistance to, even under repeated exposure.
02
Broad-Spectrum Efficacy
Effective against Gram-positive, Gram-negative bacteria, fungi, and biofilms — including MRSA, C. difficile, and carbapenem-resistant Enterobacteriaceae.
03
Defined Regulatory Path
Leadership with deep FDA regulatory expertise guides a disciplined, de-risked clinical development program designed for efficient approval and commercialization.
Market Opportunity

A Crisis Demanding
a New Solution

The Antimicrobial Resistance Crisis
AMR is projected to cause 10 million deaths annually by 2050, surpassing cancer as the world's leading cause of death. The global healthcare system is facing an existential threat that existing antibiotics cannot resolve — and the pipeline of new agents is nearly empty.
Why Now
Regulatory agencies globally are fast-tracking novel AMR solutions. CARB-X, BARDA, and NIAID are actively funding non-antibiotic approaches. aPDT is uniquely positioned as a ready-to-advance technology with decades of published evidence and no resistance liability.
Spectracore's Position
Founded by physician-scientists with direct clinical, regulatory, and trials experience, Spectracore enters with a clear-eyed understanding of the path from bench to bedside — and the credibility to execute it.
$14B
Global aPDT Market by 2030
CAGR 12.3% — Grand View Research
10M
Projected AMR Deaths / Year by 2050
WHO Global Action Plan on AMR
~700
Published aPDT Clinical Studies
PubMed indexed, 2000–2024
0%
Resistance Reported in aPDT Literature
Across all published in vitro & in vivo studies
Leadership

Built by Those Who've
Done It Before

MD
Founder & Chief Executive Officer
Physician-Scientist
Board-certified physician with deep expertise in clinical medicine, regulatory strategy, and therapeutic development. Combines frontline clinical insight with executive-level commercialization experience.
Rx
Chief Regulatory Officer
FDA Strategy Lead
Extensive experience navigating FDA pre-submission processes, 510(k), and PMA pathways for novel therapeutic modalities. Proven track record of de-risking novel device and drug classifications.
CT
Head of Clinical Development
Trials Expert
Seasoned clinical trials architect with experience designing and executing Phase I–III programs across infectious disease and wound care indications. GCP-certified and audit-ready.

* Full team profiles and CVs available under NDA upon request.

Get in Touch

Let's Build
Something
Significant.

We are engaging with strategic investors, development partners, and institutional collaborators. Pitch decks, financial models, and full diligence packages are available under NDA.

Email
invest@spectracoretherapeutics.com
Headquarters
United States
This website is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy any securities. Spectracore Therapeutics products are investigational and not approved by the FDA.